Background: It remains uncertain which diet is best for people with type 2 diabetes (T2D). Objective: We compared the effects of dietary carbohydrate restriction with fat restriction on markers of metabolic syndrome and quality of life in people with T2D. Design: This systematic review of randomized controlled trials (RCTs) and controlled clinical trials (CCTs) compares the effects of a low-carbohydrate [≤40% of energy (%)] diet with those of a low-fat (≤30%) diet over a period of ≥4 wk in patients with T2D. Two investigators independently selected studies, extracted data, and assessed risk of bias. The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach was used to assess the certainty of evidence. Pooled mean differences (MDs) and 95% CIs were calculated with the use of a random-effects model. Results: Thirty-three RCTs and 3 CCTs (n = 2161) were included. Glycated hemoglobin declined more in people who consumed lowcarbohydrate food than in those who consumed low-fat food in the short term (MD: -1.38%; 95% CI: -2.64%, -0.11%; verylow-certainty evidence). At 1 y, the MD was reduced to -0.36% (95% CI: -0.58%, -0.14%; low-certainty evidence); at 2 y, the difference had disappeared. There is low to high (majority moderate) certainty for small improvements of unclear clinical importance in plasma glucose, triglycerides, and HDL concentrations favoring lowcarbohydrate food at half of the prespecified time points. There was little to no difference in LDL concentration or any of the secondary outcomes (body weight, waist circumference, blood pressure, quality of life) in response to either of the diets (very-low-to high-certainty evidence). Conclusions: Currently available data provide low-to moderatecertainty evidence that dietary carbohydrate restriction to a maximum of 40% yields slightly better metabolic control of uncertain clinical importance than reduction in fat to a maximum of 30% in people with T2D. This systematic review is registered at http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID= CRD42017052467 as CRD42017052467.
INTRODUCTION
Type 2 diabetes (T2D) is a multifactorial disease, emanating from gene-environment interactions (1) . Diet quality and quantity are at the heart of its pathogenesis (2) . Although it is quite clear that nutrition plays a pivotal role in the pathogenesis of T2D, it remains unclear which dietary measures are most effective in ameliorating metabolic derangements. There is little doubt, however, that reduction in body fat stores dampens chronic inflammation and improves metabolic anomalies. Thus, it is perhaps unsurprising to note that dietary guidelines for T2D tend to focus on weight loss as a primary goal. In this context, the consumption of low-fat food has been advocated for many years, inspired by at least 2 assumptions. First, that because fat contains more calories per gram, consuming less fat will reduce fat stores more than restricting protein or carbohydrate intake, and second, that consumption of (saturated) fat is associated with dyslipidemia (elevated LDL-cholesterol concentrations) and cardiovascular disease, and the main complications of diabetes mellitus all relate to vascular obstruction. However, the most recent clinical guideline recommendations conclude that "as there is no single ideal dietary distribution among carbohydrates, fats and proteins for people with diabetes, distribution should be individualized while keeping total calories and metabolic goals in mind" (3) . This conclusion has been challenged in a number of reports, which claim that restriction of carbohydrates, and in particular refined carbohydrates, is most effective in redressing metabolic anomalies in T2D (4) (5) (6) . This position concurs with common sense, because carbohydrates are the only (direct) source of glucose in the diet. It goes without saying that dietary restriction of sugar and starch (chains of glucose monomers linked by glycosidic bonds) is therefore expected to lower blood glucose peaks. Moreover, because any excess glucose is readily converted into (saturated) fat by hepatic de novo lipogenesis and subsequently secreted as VLDL triglycerides (7) , the restriction of starchy food is expected to reduce plasma triglyceride concentrations. However, none of the available reports, which include several systematic reviews, specifically compared the impact of low-carbohydrate diets with that of low-fat diets on glucose control, body weight, and plasma lipid profiles in people with T2D. Indeed, the majority of these compared the effects of carbohydrate-restricted with -unrestricted diets, which increases the possibility of imbalanced energy content of comparator diets (see Discussion). We present the results of a systematic review and meta-analysis of available data comparing the effects of low-carbohydrate with low-fat dietary interventions on glucose control and other important metabolic and anthropometric variables, as well as on quality of life in individuals with T2D. Grading of Recommendations Assessment Development, and Evaluation (GRADE) methodology was used to rate the certainty of the evidence (8) .
METHODS
This systematic review is reported according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement (9) and in concordance with the corresponding prospectively registered protocol in PROSPERO (CRD42017052467) (10) .
Eligibility criteria
We included randomized controlled trials (RCTs) and controlled clinical trials (CCTs), which compared a lowcarbohydrate diet with a low-fat diet over a period of ≥4 wk in adult patients (aged ≥18 y) with T2D. A low-carbohydrate diet was defined as any dietary intervention containing ≤40% of energy (%) from carbohydrate and a low-fat diet as one containing ≤30% from fat. The value of 40% from carbohydrate was chosen as the upper limit for inclusion, because this represents the most common minimum carbohydrate intake at a global level (12) . Studies that stated clearly, in the Methods section, their intention to meet these cutoffs of energy percentages were eligible for inclusion. However, if the actual intake of any one of the macronutrients exceeded 2% above these limits, these data were not included in the final analysis. We also only included data from crossover trials that had incorporated wash-out periods of ≥4 wk between interventions. In the absence of an adequate wash-out period, we used the data from these trials only if we were able to extract the relevant data for the first phase (i.e., before the crossover), because we considered the risk of carryover effects to be prohibitive. We excluded studies that included people with other chronic diseases, except for hypertension or cardiovascular disease. Studies were also excluded if they included participants who were using systemic corticosteroids, had any (progressive) disease requiring hospital care, or included those with an eating disorder or any other disease necessitating special dietary requirements (except for sodium restriction).
Literature search
All the search strategies for the various databases (Supplemental Table 1 ) were designed and tested by a medical research librarian. The searches included the following databases-Medline, PubMed, Embase, Web of Science, Cochrane Library, Cochrane Central Register of Controlled Trials (CEN-TRAL), Emcare, Academic Search Premier, ScienceDirect, Latin American and Caribbean Health Science Information database (LILACS), and Índice Bibliográfico Español en Ciencias de Salud (IBECS)-and covered the period from inception up to 21 March 2017. Additional searches were conducted in the following trial registers (www.isrctn.com/, www.clinicaltrials.gov, http://www.anzctr.org.au/, http://apps.who.int/trialsearch/, www. clinicaltrialsregister.eu). Two review authors (EJvZ and ZF) also examined the bibliographies of the included and excluded studies and the Public Health Collaboration database (https://phcuk.org/rcts/) for further references to potentially eligible studies. Finally, we checked the bibliographic reference lists of previous systematic reviews that had covered this clinical topic.
Study selection
Two of the authors (EJvZ and ZF) independently assessed the titles and abstracts of studies identified from the searches and, if necessary, obtained and reviewed the full-text versions to establish whether they met the inclusion criteria. Any disagreements on eligibility were resolved through discussion to reach consensus and, when necessary, by involving a third author (HP). Studies that did not meet our inclusion criteria were excluded. The number of reports retrieved, the number of included and excluded studies, and the reasons for their exclusion are presented in Figure 1 .
Data extraction and risk-of-bias assessment
Two of the authors (EJvZ and ZF) independently collected study details and outcomes data using a piloted data extraction form, and any disagreements on data entry were resolved through discussion or by consultation with a third author (HP). We extracted study characteristics (design, year of publication, setting, country of origin, duration of intervention, and followup), and patients' characteristics (sample size, sex, age, inclusion and exclusion criteria, number of dropouts and reasons for loss to follow-up, baseline data, medication for diabetes). Key details were extracted on the diet (% from carbohydrates, protein, and fat; program support measures and degree of compliance; targeted intake and actual intake; whether diets were isocaloric and aimed at weight maintenance or weight loss), exercise, our prespecified primary and secondary outcomes, and information on funding and declarations of interest. The trial investigators and sponsors of included studies that were <10 y old were contacted for additional trial details and missing data.
Our primary outcomes were change from baseline in glycated hemoglobin (HbA1c) concentration in whole blood and plasma glucose, triglyceride, and HDL-and LDL-cholesterol concentrations in the fasted condition. Our secondary outcomes were change from baseline in body weight, BMI, waist circumference, blood pressure, and quality of life. We grouped data in shortterm (<8 wk), medium-low-term (≥8-16 wk), medium-highterm (≥16-26 wk), and long-term (>26 wk) measurements.
Two of the authors (EJvZ and ZF) independently assessed the risk of bias for each RCT with the use of the Cochrane Collaboration's domain-based assessment tool (11) . Inconsistencies in judgments were resolved through discussion or by involving a third author (HP). The overall risk of bias for each study was determined as follows: "low risk of bias" when all domains were assessed as low risk (plausible bias unlikely to seriously alter the results); "unclear risk of bias" when ≥1 domain was classified as an unclear risk (plausible bias that raises some doubt about the results); and "high risk of bias" when ≥1 domain was judged as being at high risk (plausible bias that seriously weakens confidence in the results). For nonrandomized controlled trials we used ROBINS-I (7-domain tool) to assess the risk of bias (13) . An overall risk of bias was assigned on the basis of the assessment of each domain as low, moderate, serious, or critical, with the minimum overall risk typically determined by the highest risk assigned in any individual domain.
Statistical analysis
All of the prespecified outcomes for this systematic review were only reported as continuous data, for which we calculated the mean differences (MDs) with their associated 95% CIs, and carried out a complete case analysis if data were missing or incomplete. Heterogeneity between the studies in effect measures was assessed by using the I ² statistic, with an I ² > 50% indicative of substantial heterogeneity. We combined studies that evaluated similar outcomes and pooled their data in a meta-analysis independently of the observed heterogeneity. Following the recommendations of the GRADE working group, we considered downgrading the certainty of evidence for inconsistency when I 2 > 50%, while taking other considerations for downgrading into account (8) . We intended to assess publication bias on the basis of the recommendations on testing for funnel plot asymmetry (14) , but the paucity of studies evaluating any of the outcomes at the same specific time points did not permit such an assessment. The lack of an adequate number of included studies reporting on the subgroups specified in our protocol precluded any attempts to carry out our planned subgroup analyses.
The data reported for our predefined outcomes were pooled, where possible, with the use of a random-effects model and presented in forest plots. All of the analyses were undertaken using RevMan 5.3 (The Nordic Cochrane Centre).
To explore sources of statistical heterogeneity between studies and to assess the robustness of our data, we conducted several sensitivity analyses. We repeated our analyses with the use of the fixed-effects model to enable an assessment of the influence of small-study effects on the results of any of the meta-analyses in which there was evidence of between-study heterogeneity (I 2 > 0%; see Supplemental Figure 1 ). We also undertook sensitivity analyses to examine the effect of excluding studies at overall high risk of bias (see Supplemental Figure 2 ) and the impact of excluding studies that were the cause of substantial heterogeneity (see Supplemental Figure 3 ).
Certainty of evidence
We applied the GRADE approach with the use of GRADE-proGDT (http://gradepro.org) to assess the certainty of evidence for the predefined outcomes, as presented in the Summary of Findings (Tables 3-6 ). This approach takes into consideration the following: study limitations (risk of bias), inconsistency of results, indirectness of evidence, imprecision, and publication bias. Two of the authors (EJvZ and TK) independently rated the certainty of evidence for the prespecified outcomes as "high," "moderate," "low," and "very low," and discrepancies were resolved by consensus or with input from a third author (ZF or HP).
RESULTS

Search results
Our searches across the databases identified 993 articles and 91 further references to abstracts. Nine additional records were found through other resources and hand-searching, and we also identified 9 ongoing trials ( Figure 1 ). After examination of the titles and abstracts and the removal of any duplicate publications, we excluded 950 references. A total of 138 full-text copies were obtained for further evaluation. Of these, we excluded 9 ongoing studies that had not published any data and 46 studies that were co-publications (studies that were published more than once, or had evaluated other outcomes from the same study population). We also excluded 47 studies (15-61) for other reasons, the most important of which were that the composition of the diets did not meet our inclusion criteria (i.e., the prespecified cutoffs) or that the actual intake during the study appeared to be higher than the agreed or prescribed percentages of carbohydrates or fat (or both). Other reasons for exclusion were that studies did not appear to have been conducted in patients with T2D, that there were insufficient details reported on the content of the diets, or that the study duration was too short. For more details, see Supplemental  Tables 2-5 .
Study characteristics
Thirty-six studies (33 RCTs and 3 CCTs), which evaluated a total of 2161 patients, were included in this systematic review . Table 1 summarizes the key characteristics of these studies. Supplemental Table 6 provides more detailed information on the 36 studies as well as the specific judgments per risk-of-bias domain for each study. Four studies included only men, 3 included only women, and the remainder included both men and women in varying proportions. Samples sizes were rather small (ranging from <20 to 60 patients) in most of the studies, with only 8 studies evaluating >100 patients (66-68, 76, 86, 89, 93, 96) . The mean age of participants was 56.6 y and was consistent across the studies (mean range: 32-65 y; majority between 50 and 60 y). A majority of the studies had a 2-arm design (n = 31), and the remainder included 3-arm studies (n = 4) and one 4-arm study. Most of the studies were conducted in Europe (n = 14) or in the United States and Canada (n = 15). One study was conducted in Mexico, 2 in Israel, 2 in Japan, and a further 2 in Australia. Study duration varied from 4 wk extending to 7 y in 1 outlying study, with an overall mean period of 33 wk (exclusion of the outlier would provide a more representative mean of 24 wk). A total of 19 studies were conducted before 2000, and the remaining 17 after the year 2000.
In 9 of the studies, the meals were provided by the hospital or were home delivered, or patients were hospitalized throughout the study (62, 64, 65, 69-71, 81, 84, 88) . In the other studies, patients underwent specific training by a dietitian, were provided with a list of foods to be consumed, and received regular followup sessions (phone calls, hospital visits) to ensure adherence to the dietary recommendations.
Eight of the studies encouraged an increase in physical activity by participants during the study period (66, 68, 72, 76, 81, 83, 87, 93) . The study by Bozzetto et al. (63) , which examined the effects of diet-exercise interaction, included a mandatory supervised exercise program in 2 of the 4 arms, but we only included data from the arms without exercise because the focus of this systematic review was a specific comparison of dietary interventions.
In 16 studies, the diets were isocaloric (62-64, 68-71, 73, 81, 85, 88, 90, 91, 93-95) . Nine studies aimed for weight reduction by calorie restriction in both diets (66, 68, 72-75, 81, 83, 93) , and in 2 studies (89, 97) only one of the diets was calorie restricted. In 8 studies, the calorie intake was adjusted to maintain constant body weight (62-65, 70, 84, 88, 95) .
The review included 17 crossover trials, and in 14 there was no washout, or the washout period was <4 wk, which we considered too short to exclude potential carryover effects. Because there were no data reported separately for each phase (data were combined for both phases), we were unable to use these 14 studies, although they matched our inclusion criteria (see Supplemental Table 4 ) (62, 64, 65, 69-71, 77, 80, 85, 88, 90-92, 95) . The metabolic effects of dietary interventions can persist for a variable length of time (depending on the nature of the intervention), and the carryover effects can bias the analysis of data obtained in the second intervention periods if the washout period is too short. The 3 remaining crossover studies had a wash-out period of ≥4 wk and provided data that we were able to include in the meta-analyses (78, 84, 94) . The data from 5 of the RCTs were unusable (see Supplemental  Table 4 ). One study (79) did not address any of our outcomes, 1 study (82) did not provide separate data for patients with type 1 diabetes and T2D, 3 other studies (76, 86, 87) targeted our criteria of a low-carbohydrate compared with a low-fat diet (%) but appeared to subsequently exceed our cutoff values by >2% at follow-up. Furthermore, in the study by Samaha et al. (86) , data are reported on some outcomes for diabetics (glucose, insulin, and HbA1c), but it is unclear how many diabetic patients remained in each intervention group throughout the study period. The report indicated that there was a 40% drop-out rate but also failed to clarify how many diabetics dropped out in each intervention group, which did not permit further analysis of the data. Overall, out of the 36 included studies, only 17 provided data that could be further analyzed and subsequently entered into the meta-analyses.
Our predefined outcomes were evaluated as follows-HbA1c (25 studies); plasma concentrations in the fasted condition: glucose (29 studies), triglycerides (31 studies), HDL cholesterol (30 studies), and LDL cholesterol (28 studies); body weight (23 studies); BMI (10 studies); waist circumference (7 studies); blood pressure (11 studies); and quality of life (5 studies).
Sources of funding were reported in all but 2 of the studies (78, 97) . Declarations of conflicts of interest were only reported in 4 studies (72, 74, 87, 96) , but we considered that either funding or conflicts of interest might have resulted in potential bias in 6 (72, 75, (90) (91) (92) 96) of the studies, in which the Sugar Foundation, Mars, or other food industry provided funding for the study or the investigators received honoraria from these entities.
Risk-of-bias assessment
The risk-of-bias assessments for the 33 included RCTs are presented in Figure 2 . We were successful in contacting trialists and clarifying trial details and subsequently amending our judgments in several of the risk-of-bias domains for 3 studies (63, 66, 94) . We further categorized the overall risk of bias for the 33 studies, 19 of which were judged to be at high risk of bias and the remaining 14 studies at unclear risk of bias. The most important reasons why studies were considered at high risk of bias was the lack of a washout period (or too short of a washout period) between diets in the crossover studies (n = 13) or a high drop-out rate (n = 8), or both and 1 study (68) appeared to be quasi-randomized. (See Table 1 for summarized assessments of risk of bias and Supplemental Table 6 for detailed risk-of-bias judgments.)
The risk-of-bias assessments for the 3 CCTs (70, 74, 83) are shown separately in Table 2 . The overall risk of bias in these studies varied from moderate to serious risk of bias.
Outcomes
Sensitivity analyses were carried out for our meta-analyses, where applicable, and are presented for our prespecified outcomes in Supplemental Figures 1-3 (see also under "Statistical analysis" above). The robustness of our results was underpinned by the minimal divergence in effect estimates between our metaanalyses and the sensitivity analyses, which at no stage reached a clinically important difference.
Change from baseline in HbA1c
This outcome was assessed and reported in 14 studies, some of which provided data within several measurement time points (63, 66-68, 72, 73, 78, 83, 84, 89, 93, 94, 96, 97) . In contrast with low-fat diets, low-carbohydrate diets improved HbA1c at almost all time points, but the difference diminished over time, which is unremarkable in view of the well-acknowledged difficulties of adherence to dietary changes over extended periods of time (see Figure 3 ; very-low-to moderate-certainty evidence).
Change from baseline in fasting plasma glucose concentration
Data for this outcome were provided by 14 studies (63, 67, 68, 72, 74, 75, 78, 81, 83, 89, 93, 94, 96, 97 ; see Figure 4 ). In 2 time windows, the low-carbohydrate diets induced a greater decrease in fasting glucose concentration than the low-fat diets (≥8-16 wk and ≥16-26 wk; moderate-certainty evidence).
Change from baseline in fasting triglyceride concentration
Fifteen studies evaluated triglycerides in the fasting condition (63, 66-68, 72-75, 78, 81, 84, 93, 94, 96, 97 ; see Figure 5 ). Although there was a trend toward an effect in favor of the low-carbohydrate data, only the data reported beyond 16 wk favored the low-carbohydrate diets (moderate-to high-certainty evidence).
Change from baseline in fasting HDL-cholesterol concentration
This outcome was assessed in 12 studies (63, 66, 68, 72-74, 78, 81, 84, 93, 94, 96; see Figure 6 ). The pooled data at several time points showed an increase in HDL cholesterol in favor of the low-carbohydrate diets (low-to moderatecertainty evidence), which persisted at 2 y, but the latter was based on data available from only 2 of the studies (73, 93) .
Change from baseline in fasting LDL-cholesterol concentration
Twelve studies reported data on this outcome (63, 66, 68, 72-74, 78, 84, 93, 94, 96, 97) , with little to no difference shown between the 2 diet arms at any time point (moderate-to highcertainty evidence; see Figure 7 ).
Change from baseline in body weight
A total of 16 studies provided data for this outcome ( Figure 4 ). There was a small effect (MD: −2.04 kg, 95% CI: −3.23, −0.85 kg) only at ≥8-16 wk in favor of low-carbohydrate food (high-certainty evidence).
Change from baseline in BMI
Seven studies evaluated the effect of the 2 diets on BMI over time (68, 72, 73, 83, 93, 94, 97) . There was little to no difference between the 2 dietary approaches at the assessed time points (lowto high-certainty evidence; see Supplemental Figure 5 ).
Change from baseline in waist circumference
Change in waist circumference was measured in 6 studies (63, 68, 72, 73, 93, 96) . There was no to little difference between lowcarbohydrate food and low-fat food at the assessed time points (low-to high-certainty evidence; see Supplemental Figure 6 ).
Change from baseline in blood pressure
Seven studies investigated the effects of both types of diets on blood pressure (66, 73, 84, 93, 94, 96, 97) . For both systolic as well as diastolic blood pressure, there were possibly no differences in effects between the 2 diets (low-to high-certainty evidence), except at 6 mo, where diastolic blood pressure probably declined more with low-carbohydrate food (MD: −1.91 mm Hg; 95% CI: 
Change from baseline in quality of life
Four studies provided data on quality of life (66, 73, 96, 97) . The data in the study by Davis et al. (66) were reported in a subsequent article published in 2012 (see Supplemental Table 5 ), but they were not reported separately per treatment arm, which did not permit reliable conclusions to be drawn with regard to the effects of each individual diet on quality of life. The authors reported that the primary goal of their analysis was "to determine whether the dietary strategy used for weight loss would have differential effects on quality of life." Of the 46 out of 105 participants who completed the study, there were reductions in the Diabetes-39 questionnaire scores related to sexual function, energy, and mobility, but the investigators "did not observe any changes in diabetes-specific quality of life measures that differed between dietary arms." Data of Wolever et al. (96) were also addressed in a subsequent paper (see Supplemental Table 5 ). A Quality of Life questionnaire was used, which was adapted from validated questionnaires. No exact data were provided but the authors reported "no significant differences between baseline and end of study and no significant changes among diets."
Effects of dietary interventions per time window
Short-term measurements (<8 weeks)
The data up to 8 wk as well as the certainty of evidence are summarized in Table 3 . However, because the possible causes of heterogeneity are not fully captured in this table, we provide details to accompany this and the following tables.
The substantial heterogeneity between studies for HbA1c is likely due to a significant increase in HbA1c in the highcarbohydrate (low-fat) group in the study by Lerman-Garber et al. (78) , which may be attributable to the baseline imbalance of HbA1c, by the relatively high (60%) carbohydrate content of the high-carbohydrate diet, or both. Furthermore, consideration should also be given to the rather large (35%) drop-out rate in this study.
For fasting glucose, heterogeneity was almost completely caused by the study by Hockaday et al. (75) , in which the low-fat-diet group did clearly better than the low-carbohydrate group. However, this may have been due to the fact that plasma glucose concentrations at baseline were substantially higher in the participants receiving the low-fat diet.
Heterogeneity between studies for fasting triglycerides was primarily caused by the study by Gumbiner et al. (74) , which reported a considerable reduction in plasma triglyceride concentrations in participants following the low-carbohydrate diet. This may have been due to the significant difference in macronutrient composition between the dietary interventions in this study. The low-carbohydrate diet had only 9.5% from carbohydrate and 70% from fat, whereas the low-fat diet had 70% from carbohydrates and only 10% from fat. All of the other included studies had ±40% from carbohydrates in their lowcarbohydrate intervention.
The heterogeneity between studies for fasting HDL cholesterol was largely attributable to the results reported by Miyashita et al. (81) . It remains unclear why the HDL-cholesterol concentrations increased more in response to low-carbohydrate food in this study (even in the absence of effects on triglyceride concentrations) than the other included studies.
Medium-term measurements (≥8-16 wk)
The results for this time window for each of the prespecified outcomes as well as the certainty of the evidence are presented in Table 4 . Heterogeneity for the pooled data on HbA1c was primarily caused by the study by Nielsen et al. (83) . There was a larger reduction in HbA1c in this study than in the other 3 studies, probably because the carbohydrate content of the lowcarbohydrate diet in this study was only 20%, as opposed to 30-40% in the other 3 studies. Moreover, this CCT was at serious risk of bias, because participants who were assigned to low-carbohydrate food were recruited via an informational meeting on alternative dietary interventions, whereas the control group did not attend that meeting for unclear reasons (but likely because they were not interested). Thus, the intervention group showed interest in their condition and in alternative dietary strategies, whereas participants in the control group were apparently less than interested. Affinity with or preference for a specific intervention is most likely to have an impact on the outcome.
With regard to change from baseline in BMI, 2 studies compared both low-carbohydrate and low-fat diets, but they were very different in other respects. The CCT (83), as just mentioned, had a serious risk of bias (see above), and the dietary interventions studied were calorie restricted and very low carbohydrate (20%), and participants were instructed to exercise 30 min/d. Conversely, in the study by Walker et al. (94) , the lowcarbohydrate intervention contained 40% from carbohydrate, it was not calorie restricted, and the participants were advised to maintain usual physical activity. These differences may, to a large extent, explain the heterogeneity between the studies.
The heterogeneity in the data of change in systolic blood pressure [greater decline with low-carbohydrate food in Davis et al. (66) ] may have been caused by the fact that the % of carbohydrates of actual intake in the low-carbohydrate group at that time point was 24% in the study by Davis 
Medium-term measurement (≥16-26 wk)
Data on the prespecified outcomes as well as the certainty of evidence for this time period are shown in Table 5 . Heterogeneity between studies for HbA1c was caused by 2 of the studies (67, 93) . The reductions in HbA1c in both of these were substantial in both diet arms, but it remains unclear why the difference in HbA1c reduction between low-carbohydrate and low-fat diets in these studies was relatively small. The participant characteristics, medications used (and discontinuance of medication during the study), dietary composition, or dropout rate do not appear to differ significantly between studies. Tay et al. (93) reported a significant difference in favor of the low-carbohydrate intervention between the 2 diet groups in participants with a high HbA1c at baseline (>7.8%), but there was no difference between groups as a whole.
Heterogeneity between studies for fasting glucose was primarily caused by the same 2 studies (67, 93) . It remains unclear why these studies differed from the other studies in terms of the response of fasting plasma glucose concentrations to dietary intervention. The heterogeneity between studies for fasting HDL cholesterol was fully attributable to the slight reduction in HDL cholesterol in response to low-carbohydrate food in 2 of the studies (67, 72) . This discordance in the data may be due to the relatively high baseline HDL-cholesterol concentrations in both studies, which paves the way for random changes (regression) toward a lower mean on subsequent measurement. We were unable to identify other differences between the included studies that might provide an explanation for the heterogeneity or variability in HDL-cholesterol concentrations in response to the dietary intervention.
For the outcome of change from baseline in body weight as well as BMI, heterogeneity was essentially caused by 2 of the studies (72, 83) , which showed the greatest differences in body weight favoring the low-carbohydrate group. The CCT by Nielsen et al. (83) was at serious risk of bias, as discussed under the former time window, with the participants in the low-carbohydrate diet group being presumably more adherent due to the counseling ahead of the study. Although the energy content of the actual dietary intake was not reported, the verylow-carbohydrate diet utilized in the study by Goday et al. (72) had far fewer calories (600-800 kcal in the "active" phase) than the low-fat diet (500-1000 kcal restriction according to each individual's basal metabolic rate). All of the heterogeneity between the studies evaluating change from baseline in waist circumference can be attributed to Goday et al. (72) , perhaps because the low-carbohydrate ketogenic diet in this study had far fewer calories than the low-fat intervention, whereas both interventions were energy-matched in the other studies (73, 93) . Supplemental Table 5 ). Data were collected by using the generic Short Form-36 (SF-36), a 36-item questionnaire covering 8 health domains, with each domain scoring from 0 to 100 (higher score indicating better quality of life). The investigators calculated both the combined physical component score (PCS) and the mental component score (MCS). The questionnaire was completed at month 6 by 23 patients in the low-carbohydrate group and by 22 in the low-fat intervention group. The mean ± SD change from baseline in PCS at 6 mo was −0.90 ± 7.44 in the low-carbohydrate group compared with 0.50 ± 6.30 in the low-fat group. The mean ± SD change from baseline in MCS was −1.70 ± 8.43 in the lowcarbohydrate diet group compared with 1.80 ± 6.30 in the low-fat group.
In the study by Yamada et al. (97) , 2 different instruments were used: the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and the Problem Areas in Diabetes scale (PAID). The DTSQ measures treatment satisfaction in patients with diabetes and covers 6 satisfaction items on a 7-point Likert scale from 0 to 6, with a maximum total of 36 points, with higher scores indicating greater satisfaction (98) . The PAID score covers a 20-item survey and evaluates the degree to which diabetes management or feelings about diabetes are problematic to people with diabetes (99) . Each item is scored on a Likert scale ranging from 0 to 4, with the sum of all item scores multiplied by 1.25 to obtain the overall PAID score (range from 0 to 100), with a higher score reflecting more significant diabetes-related emotional distress. For the DTSQ, the total score (± SD) increased from 24.0 ± 6.6 by 3.60 ± 3.98 at 6 mo in the 12 patients following a lowcarbohydrate diet compared with an increase from 21.6 ± 3.3 by 3.10 ± 2.72 in the 12 patients following the calorie-restricted (low-fat) diet. Both diets showed small improvements in quality of life with no to little difference between the diets. The PAID scores (± SD) changed from 42.1 ± 13.5 by −4.30 ± 8.12 in the low-carbohydrate-diet group and from 57.8 ± 12.6 by −0.60 ± 7.78 in the calorie-restricted (low-fat) diet group. Although the magnitude of changes in both quality-of-life instruments required for clinical significance (minimal important difference) has not been established, the subtle improvements measured in both intervention arms are unlikely to be of clinical relevance.
Long-term measurement (>26 weeks)
The long-term measurement results of the prespecified outcomes and the certainty of evidence are summarized in Table 6 . The substantial heterogeneity between studies of change from baseline in fasting glucose was almost fully attributable to the differing results of 2 of the studies (75, 96) . The beneficial effect of low-fat food in the study by Hockaday et al. (75) may have been biased by the higher glucose concentrations at baseline in the participants assigned to receive low-fat food. The relatively minor difference in fasting glucose concentrations in response to low-fat compared with low-carbohydrate food in the study by Wolever et al. (96) may have been due to the fact that the low-fat intervention contained only low-glycemic-index carbohydrates 2 High certainty: we are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: We are moderately confident in the effect estimate (the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different). Low certainty: our confidence in the effect estimate is limited (the true effect may be substantially different from the estimate of the effect. Very low certainty: we have very little confidence in the effect estimate (the true effect is likely to be substantially different from the estimate of effect).
3 Downgraded 1 level for serious risk of bias. One study had a 35% drop-out rate. 4 Downgraded 1 level for serious inconsistency (I 2 = 68%). 5 Downgraded 1 level for serious imprecision, low total sample size. 6 One CCT. 7 We did not downgrade for risk of bias for the study at high risk of bias, because removing the study did not really alter the effect estimate. 8 Downgraded 1 level for serious inconsistency (I 2 = 81%). 9 We did not downgrade for imprecision. Although the minimal important difference is not established, based on clinical expertise reductions of <3 mmol/L are not considered to be important. Therefore, the effect estimate is rather precise. 10 Downgraded 1 level for serious inconsistency (I 2 = 79%). 11 We did not downgrade for imprecision. We considered reductions of <1 mmol/L not to be important to patients. Therefore, the effect estimate is rather precise. 12 Downgraded 1 level for serious inconsistency (I 2 = 73%). 13 Downgraded 1 level for serious imprecision. Low sample size and the lower boundary of the 95% CI included no effect. 14 We did not downgrade for risk of bias of the CCT or the high drop-out rate of another study because removing these had no important effect on the effect estimate. 15 Downgraded 2 levels for very serious imprecision. Very low sample size, wide CI.
within the carbohydrate component. In fact, in this study, the effects of low-fat, low-glycemic-index food were compared with those of low-carbohydrate food.
The heterogeneity between the studies for change from baseline in fasting triglycerides was fully attributable to the more substantial decrease in triglycerides in response to carbohydrate restriction in one of the studies (68) . A possible explanation could be that baseline plasma triglyceride concentrations were substantially higher in this study than in any of the other included studies (elevated concentrations almost always predict better response).
The heterogeneity between the studies for pooled data on fasting HDL cholesterol is fully explained by the relatively robust increase in HDL-cholesterol concentrations in response to low-carbohydrate food in the study by Elhayany et al. (68) , which is most likely explained by the considerable concomitant decline in plasma triglyceride concentrations achieved in that study. Reduction in circulating (VLDL) triglycerides limits the exchange of cholesteryl esters between HDL and VLDL particles and thereby increases HDL cholesterol.
Almost all of the heterogeneity between the studies of the meta-analysis for data on change from baseline in LDL cholesterol was caused by the data from 1 study (68) , which reported diametrically opposing results (larger decline in LDL cholesterol in response to the low-carbohydrate diet). This difference is difficult to explain but may be due to the differences in sex distribution and ethnicity between participants. It may also reflect differences in diet quality between the studies. The only study that addressed quality of life at 1 and 2 y was Guldbrand et al. (73) . At 12 mo, the mean ± SD change from baseline in the low-carbohydrate group (n = 27) for the PCS was 2.60 ± 6.50 and 0.60 ± 6.32 in the low-fat group (n = 28) and for the MCS was 0.90 ± 4.34 compared with 1.10 ± 6.11. At ⊕ Very low [11] [12] [13] We are uncertain about the effect of a low-carbohydrate diet in reducing BMI compared with a low-fat diet Change from baseline in waist circumference (follow-up-mean: 8 wk)
The mean change from baseline in waist circumference was 1 cm 
DISCUSSION
Principal findings and interpretation
This systematic review of 36 RCTs and CCTs (including 2161 patients) is the first, to our knowledge, to comprehensively and specifically compare the effects of low-carbohydrate with low-fat food on glucose control, the plasma lipid cardiovascular risk profile, and body weight of persons with T2D. Our results suggest that there is, in general, little to no difference between the metabolic effects of diets containing ≤40% from carbohydrates ("low carb") and diets containing ≤30% from fat ("low fat"). A low-carbohydrate diet may reduce HbA1c compared with a low-fat diet, particularly in the short and medium term up to 1 y, but we are uncertain about this effect. At 2 y, the difference between the effects of either diet on HbA1c had disappeared. The fact that all metabolic measurements tended to return to baseline values in both groups after 2 y suggests that lack of compliance with dietary prescriptions may have played a role. Although carbohydrate restriction more clearly improves other metabolic variables at many of the prespecified time points, the differences with the effects of low-fat food are of doubtful clinical importance and supported by only low to moderately certain evidence. Because the minimal clinically important difference for most of these metabolic variables has not been determined, our inference with regard to clinical meaning is arguable.
Both dietary strategies similarly affected LDL-cholesterol concentrations, which may come as a surprise, because (some) SFAs tend to increase LDL-cholesterol concentrations. However, this is particularly true if dietary PUFAs are substituted by SFAs. Substitution of carbohydrates by saturated fat has less of an effect on LDL-cholesterol concentrations (100) . Blood pressure response (systolic as well as diastolic) was also not significantly different, although low-carbohydrate food may reduce diastolic pressure slightly more than low-fat food in the medium term. All of these metabolic effects occur in the face of little to no differences in losses of body weight or waist circumference. There may be no important improvement in quality of life in response to either dietary strategy in the few studies assessing this outcome. The certainty of evidence for the secondary outcomes varied from very low to high, but is predominantly low at the various time points. Although all measurable differences between the metabolic effects of low-carbohydrate diets and those of low-fat diets were in favor of low-carbohydrate food, they were small, of uncertain clinical importance, and supported by only low-to moderatecertainty evidence according to GRADE. These observations are counterintuitive, because carbohydrates are the only (direct) source of glucose in our diet, and restriction of carbohydrate consumption is therefore expected to lower blood glucose and HbA1c as well as triglyceride concentrations. Substantial clinical and methodologic heterogeneity between eligible studies may contribute to the apparent lack of differences (see below). The relatively mild restriction of carbohydrate content of most lowcarbohydrate diet interventions included in the review (25-40%) may have also played a role. However, the results of 3 studies comparing very-low-carbohydrate ketogenic diets with low-fat interventions (72, 74, 93) do not substantially deviate from those of other included trials.
Strengths and limitations of the review
The key strengths of our review are underlined by the more prescriptive approach used in setting out our selection criteria, A low-carbohydrate diet may result in little to no difference in change in quality of life compared with a low-fat diet which enabled the answering of a clearly defined clinical question on the comparison of 2 explicit dietary strategies for management of T2D. Any methodologic difference between this review and earlier reviews is most likely reflected in the rapidly evolving nature of the process of conducting systematic reviews, such as the use of the GRADE approach to evaluate the certainty of evidence.
The high degree of clinical and methodologic heterogeneity between the included studies may be the most important reason for the apparent lack of relevant distinction between the effects of both dietary strategies. For example, the energy percentage of macronutrients in the prescription diets differed considerably. Some low-carbohydrate interventions were indeed very low (<20%) in carbohydrate (72, 74, 93) , whereas others were only mildly restrictive, and previous reports suggest that HbA1c declines in proportion to the energy percentage of carbohydrates in the diet (10) . Similarly, in some studies (74, 81) , the fat content of the low-fat intervention was much lower (<15%) than in others. Moreover, the nature of the fat component of low-carbohydrate diets differed considerably between studies, which is a potential confounder of study outcomes, because distinct fatty acids differentially affect (glucose) metabolism (101) . In addition, the quality of the carbohydrate component (simple or complex) of interventions often remains obscure, although it is of critical importance for the metabolic response to dietary regimes (102) . Numerous other aspects differed considerably between studies, including calorie content, exercise prescription, provision of food by the study center, and reporting of actual food intake. Medication regimes (glucose-, blood pressure-, and lipid-lowering) were modified in some studies, whereas they remained unchanged in others. Some of the studies included medication-naïve patients, whereas other reports failed to document medication details adequately. Notably, and significantly, in all of the studies that included patients taking medication and that adequately reported eventual adaptations (66, 73, 83, 93) , with the exception of one (67), glucoselowering drug doses were reduced in participants who consumed low-carbohydrate food, but not in those consuming low-fat food. Unfortunately, inconsistent methods of quantification and reporting precluded reliable statistical analysis of changes in drug doses.
Comparison to other (systematic) reviews
We identified 21 systematic reviews and evidence syntheses focusing on the effects of low-carbohydrate diets on metabolic outcome variables, dating back to 2006 (for a complete list, see Supplemental Table 7 ). Only one of these specifically compared the effects of a low-carbohydrate diet with those of low-fat diets on components of the metabolic syndrome in the treatment of T2D (103) . The low-carbohydrate dietary interventions in the studies included in the review contained <40% from carbohydrate, and the low-fat diets contained <25% from fat. The investigators concluded that "replacing fat with carbohydrate could deteriorate insulin resistance," with adverse effects on triglycerides and HDL cholesterol (which could be avoided by energy restriction). There were no significant differences between the effects of either diet on HbA1c or blood glucose concentration in the fasted condition. However, the studies included in the review lasted for a maximum of 12 wk, with the vast majority lasting only 2-6 wk, which is far too short a period to reliably judge the effects on HbA1c. The other available reviews of low-carbohydrate interventions had either different outcome parameters (primarily weight loss), included studies with other comparison diets, or focused on other target groups (i.e., obese individuals).
Implications of the findings
This analysis does not support the long-held preference for low-fat diets as the default dietary intervention for T2D. Instead, the results suggest that, if it fits the patients' preferences, restriction of carbohydrates may be slightly better, although the clinical benefits are uncertain.
Unanswered questions and future research
Randomized controlled intervention studies comparing the effects of very-low-carbohydrate (ketogenic) diets with those of low-fat diets in persons with T2D, wherein drug dosing is one of the primary study outcomes, are urgently needed. Moreover, the clinical importance of personalized dietary interventions is a major issue that requires evaluation in future studies. It is highly unlikely that a "one size" solution fits all patients equally well. Indeed, it has been shown that healthy people eating identical meals present highly variable postmeal glucose responses (104) . This is probably also true in persons with T2D. Some studies (105) suggest that the primary site of insulin resistance (liver, muscle, adipose, or combinations thereof) dictates the optimal diet composition for individuals with T2D.
Finally, because it appears that the key challenge with dietary interventions is in ensuring their long-term adherence, future studies should focus more on methods to sustain necessary adaptations. This will require a comprehensive systems approach, in which personal preferences, personality traits, socioeconomic status, and family circumstances, in addition to personal aspects of physiology, should be taken into account (106, 107) .
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